title: [Treatment of peritoneal mesothelioma using cytoreduction and intraperitoneal hyperthermic chemotherapy].
abstract: Malignant mesothelioma of the peritoneum is a rare tumor for which the therapeutic approach has not yet been standardized. Cytoreductive surgery and hyperthermic antiblastic peritoneal perfusion (HAPP) may be effective in the treatment of this neoplasm. From 1995 to March 2003, we operated 24 patients with malignant peritoneal mesothelioma. Nineteen times we were able to perform radical surgery and HAPP: 6 CC-0, 10 CC-1 and 3 CC-2 (nodules smaller than 1 cm). HAPP was performed by the original "semi-closed" technique, using MMC+ CDDP in 3 patients, CDDP + doxorubicin in 15 patients, only doxorubicin in 1 patient).
  
  
  RESULTS
  Operating mortality was 11% and postoperative morbidity was 26%. 4 patients are DOD (40, 20, and 2 at 2 months); 5 patients are AWD (72, 34, 25, and 2 at 15 months); 8 patients are NED (81, 47, 2 at 20 months, 16, 13, 12 months, 1 patient recently operated). The median survival is 40 months. The high rate of morbidity and mortality is due to the presence of postoperative paraneoplastic syndromes, with alterations of coagulation and onset of ARDS. Therefore the good survival results make the methodic one of the best options in the treatment of the disease.
authors.affiliation: Centro di Chirurgia Oncologica Avanzata, Torino.
authors.forename: D
authors.initials: D
authors.lastname: Costamagna
authors.forename: S
authors.initials: S
authors.lastname: Scuderi
authors.forename: M
authors.initials: M
authors.lastname: Vaira
authors.forename: R
authors.initials: R
authors.lastname: Barone
authors.forename: M
authors.initials: M
authors.lastname: De Simone
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001778:Blood Coagulation Disorders / Q000209:etiology / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D016685:Mitomycin / Q000008:administration & dosage; D010257:Paraneoplastic Syndromes / Q000209:etiology / Q000401:mortality; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D011183:Postoperative Complications / Q000209:etiology / Q000401:mortality; D012128:Respiratory Distress Syndrome / Q000209:etiology / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin